Cells, mediators and Toll-like receptors in COPD
Chronic obstructive pulmonary disease (COPD) is a global health problem. Being a progressive disease characterized by inflammation, it deteriorates pulmonary functioning. Research has focused on airway inflammation, oxidative stress, and remodelling of the airways. Macrophages, neutrophils and T cel...
Gespeichert in:
Veröffentlicht in: | European journal of pharmacology 2008-05, Vol.585 (2-3), p.346-353 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 353 |
---|---|
container_issue | 2-3 |
container_start_page | 346 |
container_title | European journal of pharmacology |
container_volume | 585 |
creator | Sarir, Hadi Henricks, Paul A.J. van Houwelingen, Anneke H. Nijkamp, Frans P. Folkerts, Gert |
description | Chronic obstructive pulmonary disease (COPD) is a global health problem. Being a progressive disease characterized by inflammation, it deteriorates pulmonary functioning. Research has focused on airway inflammation, oxidative stress, and remodelling of the airways. Macrophages, neutrophils and T cells are thought to be important key players. A number of new research topics received special attention in the last years. The combined use of inhaled corticosteroids and long-acting β2-adrenoceptor agonists produces better control of symptoms and lung function than that of the use of either compound alone. Furthermore, collagen breakdown products might be involved in the recruitment and activation of inflammatory cells by which the process of airway remodelling becomes self-sustaining. Also, TLR (Toll-like receptor)-based signalling pathways seem to be involved in the pathogenesis of COPD. These new findings may lead to new therapeutic strategies to stop the process of inflammation and self-destruction in the airways of COPD patients. |
doi_str_mv | 10.1016/j.ejphar.2008.03.009 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69135958</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299908002902</els_id><sourcerecordid>69135958</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-4a0405bc3c470235893a2ccbf3b34a6cd724c6d3b37c7078b56da99ce4cf19813</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMo7vrxD0R60ZOtkyb9yEWQ-gkL62E9h3SaYmq3XZOu4L83a4vePA0zPO8w8xByRiGiQNPrJtLN5k3ZKAbII2ARgNgjc5pnIoSMxvtkDkB5GAshZuTIuQYAEhEnh2RGc05B0HROoNBt666Cta6MGnrrAtVVwapv27A17zqwGvXmZ266oFi-3J2Qg1q1Tp9O9Zi8PtyviqdwsXx8Lm4XITIBQ8gVcEhKZMgziFmSC6ZixLJmJeMqxSqLOaaV7zLMIMvLJK2UEKg51lTklB2Ty3HvxvYfW-0GuTYO_bGq0_3WyVRQlogk9yAfQbS9c1bXcmPNWtkvSUHuTMlGjqbkzpQEJr0pHzuf9m9L__xfaFLjgYsJUA5VW1vVoXG_XAyMAxWJ525GTnsbn0Zb6dDoDr1QL2-QVW_-v-QbByeGcg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69135958</pqid></control><display><type>article</type><title>Cells, mediators and Toll-like receptors in COPD</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Sarir, Hadi ; Henricks, Paul A.J. ; van Houwelingen, Anneke H. ; Nijkamp, Frans P. ; Folkerts, Gert</creator><creatorcontrib>Sarir, Hadi ; Henricks, Paul A.J. ; van Houwelingen, Anneke H. ; Nijkamp, Frans P. ; Folkerts, Gert</creatorcontrib><description>Chronic obstructive pulmonary disease (COPD) is a global health problem. Being a progressive disease characterized by inflammation, it deteriorates pulmonary functioning. Research has focused on airway inflammation, oxidative stress, and remodelling of the airways. Macrophages, neutrophils and T cells are thought to be important key players. A number of new research topics received special attention in the last years. The combined use of inhaled corticosteroids and long-acting β2-adrenoceptor agonists produces better control of symptoms and lung function than that of the use of either compound alone. Furthermore, collagen breakdown products might be involved in the recruitment and activation of inflammatory cells by which the process of airway remodelling becomes self-sustaining. Also, TLR (Toll-like receptor)-based signalling pathways seem to be involved in the pathogenesis of COPD. These new findings may lead to new therapeutic strategies to stop the process of inflammation and self-destruction in the airways of COPD patients.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2008.03.009</identifier><identifier>PMID: 18410916</identifier><identifier>CODEN: EJPHAZ</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Adrenal Cortex Hormones - therapeutic use ; Adrenergic beta-Agonists - therapeutic use ; Animals ; Biological and medical sciences ; Chemokine ; Chemokines - physiology ; Chronic obstructive pulmonary disease, asthma ; COPD ; Corticosteroid ; Cytokines - physiology ; Epithelial Cells - physiology ; Humans ; Inflammation Mediators - physiology ; Leukocytes - physiology ; Medical sciences ; PGP ; Pharmacology. Drug treatments ; Pneumology ; Pulmonary Disease, Chronic Obstructive - drug therapy ; Pulmonary Disease, Chronic Obstructive - etiology ; Pulmonary Disease, Chronic Obstructive - pathology ; Pulmonary Disease, Chronic Obstructive - physiopathology ; Toll-like receptor ; Toll-Like Receptors - drug effects ; Toll-Like Receptors - physiology ; β2-adrenoceptor agonist</subject><ispartof>European journal of pharmacology, 2008-05, Vol.585 (2-3), p.346-353</ispartof><rights>2008 Elsevier B.V.</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-4a0405bc3c470235893a2ccbf3b34a6cd724c6d3b37c7078b56da99ce4cf19813</citedby><cites>FETCH-LOGICAL-c390t-4a0405bc3c470235893a2ccbf3b34a6cd724c6d3b37c7078b56da99ce4cf19813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejphar.2008.03.009$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20340195$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18410916$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sarir, Hadi</creatorcontrib><creatorcontrib>Henricks, Paul A.J.</creatorcontrib><creatorcontrib>van Houwelingen, Anneke H.</creatorcontrib><creatorcontrib>Nijkamp, Frans P.</creatorcontrib><creatorcontrib>Folkerts, Gert</creatorcontrib><title>Cells, mediators and Toll-like receptors in COPD</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Chronic obstructive pulmonary disease (COPD) is a global health problem. Being a progressive disease characterized by inflammation, it deteriorates pulmonary functioning. Research has focused on airway inflammation, oxidative stress, and remodelling of the airways. Macrophages, neutrophils and T cells are thought to be important key players. A number of new research topics received special attention in the last years. The combined use of inhaled corticosteroids and long-acting β2-adrenoceptor agonists produces better control of symptoms and lung function than that of the use of either compound alone. Furthermore, collagen breakdown products might be involved in the recruitment and activation of inflammatory cells by which the process of airway remodelling becomes self-sustaining. Also, TLR (Toll-like receptor)-based signalling pathways seem to be involved in the pathogenesis of COPD. These new findings may lead to new therapeutic strategies to stop the process of inflammation and self-destruction in the airways of COPD patients.</description><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Adrenergic beta-Agonists - therapeutic use</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Chemokine</subject><subject>Chemokines - physiology</subject><subject>Chronic obstructive pulmonary disease, asthma</subject><subject>COPD</subject><subject>Corticosteroid</subject><subject>Cytokines - physiology</subject><subject>Epithelial Cells - physiology</subject><subject>Humans</subject><subject>Inflammation Mediators - physiology</subject><subject>Leukocytes - physiology</subject><subject>Medical sciences</subject><subject>PGP</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumology</subject><subject>Pulmonary Disease, Chronic Obstructive - drug therapy</subject><subject>Pulmonary Disease, Chronic Obstructive - etiology</subject><subject>Pulmonary Disease, Chronic Obstructive - pathology</subject><subject>Pulmonary Disease, Chronic Obstructive - physiopathology</subject><subject>Toll-like receptor</subject><subject>Toll-Like Receptors - drug effects</subject><subject>Toll-Like Receptors - physiology</subject><subject>β2-adrenoceptor agonist</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAQhoMo7vrxD0R60ZOtkyb9yEWQ-gkL62E9h3SaYmq3XZOu4L83a4vePA0zPO8w8xByRiGiQNPrJtLN5k3ZKAbII2ARgNgjc5pnIoSMxvtkDkB5GAshZuTIuQYAEhEnh2RGc05B0HROoNBt666Cta6MGnrrAtVVwapv27A17zqwGvXmZ266oFi-3J2Qg1q1Tp9O9Zi8PtyviqdwsXx8Lm4XITIBQ8gVcEhKZMgziFmSC6ZixLJmJeMqxSqLOaaV7zLMIMvLJK2UEKg51lTklB2Ty3HvxvYfW-0GuTYO_bGq0_3WyVRQlogk9yAfQbS9c1bXcmPNWtkvSUHuTMlGjqbkzpQEJr0pHzuf9m9L__xfaFLjgYsJUA5VW1vVoXG_XAyMAxWJ525GTnsbn0Zb6dDoDr1QL2-QVW_-v-QbByeGcg</recordid><startdate>20080513</startdate><enddate>20080513</enddate><creator>Sarir, Hadi</creator><creator>Henricks, Paul A.J.</creator><creator>van Houwelingen, Anneke H.</creator><creator>Nijkamp, Frans P.</creator><creator>Folkerts, Gert</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080513</creationdate><title>Cells, mediators and Toll-like receptors in COPD</title><author>Sarir, Hadi ; Henricks, Paul A.J. ; van Houwelingen, Anneke H. ; Nijkamp, Frans P. ; Folkerts, Gert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-4a0405bc3c470235893a2ccbf3b34a6cd724c6d3b37c7078b56da99ce4cf19813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Adrenergic beta-Agonists - therapeutic use</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Chemokine</topic><topic>Chemokines - physiology</topic><topic>Chronic obstructive pulmonary disease, asthma</topic><topic>COPD</topic><topic>Corticosteroid</topic><topic>Cytokines - physiology</topic><topic>Epithelial Cells - physiology</topic><topic>Humans</topic><topic>Inflammation Mediators - physiology</topic><topic>Leukocytes - physiology</topic><topic>Medical sciences</topic><topic>PGP</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumology</topic><topic>Pulmonary Disease, Chronic Obstructive - drug therapy</topic><topic>Pulmonary Disease, Chronic Obstructive - etiology</topic><topic>Pulmonary Disease, Chronic Obstructive - pathology</topic><topic>Pulmonary Disease, Chronic Obstructive - physiopathology</topic><topic>Toll-like receptor</topic><topic>Toll-Like Receptors - drug effects</topic><topic>Toll-Like Receptors - physiology</topic><topic>β2-adrenoceptor agonist</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sarir, Hadi</creatorcontrib><creatorcontrib>Henricks, Paul A.J.</creatorcontrib><creatorcontrib>van Houwelingen, Anneke H.</creatorcontrib><creatorcontrib>Nijkamp, Frans P.</creatorcontrib><creatorcontrib>Folkerts, Gert</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sarir, Hadi</au><au>Henricks, Paul A.J.</au><au>van Houwelingen, Anneke H.</au><au>Nijkamp, Frans P.</au><au>Folkerts, Gert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cells, mediators and Toll-like receptors in COPD</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2008-05-13</date><risdate>2008</risdate><volume>585</volume><issue>2-3</issue><spage>346</spage><epage>353</epage><pages>346-353</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><coden>EJPHAZ</coden><abstract>Chronic obstructive pulmonary disease (COPD) is a global health problem. Being a progressive disease characterized by inflammation, it deteriorates pulmonary functioning. Research has focused on airway inflammation, oxidative stress, and remodelling of the airways. Macrophages, neutrophils and T cells are thought to be important key players. A number of new research topics received special attention in the last years. The combined use of inhaled corticosteroids and long-acting β2-adrenoceptor agonists produces better control of symptoms and lung function than that of the use of either compound alone. Furthermore, collagen breakdown products might be involved in the recruitment and activation of inflammatory cells by which the process of airway remodelling becomes self-sustaining. Also, TLR (Toll-like receptor)-based signalling pathways seem to be involved in the pathogenesis of COPD. These new findings may lead to new therapeutic strategies to stop the process of inflammation and self-destruction in the airways of COPD patients.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>18410916</pmid><doi>10.1016/j.ejphar.2008.03.009</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-2999 |
ispartof | European journal of pharmacology, 2008-05, Vol.585 (2-3), p.346-353 |
issn | 0014-2999 1879-0712 |
language | eng |
recordid | cdi_proquest_miscellaneous_69135958 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Adrenal Cortex Hormones - therapeutic use Adrenergic beta-Agonists - therapeutic use Animals Biological and medical sciences Chemokine Chemokines - physiology Chronic obstructive pulmonary disease, asthma COPD Corticosteroid Cytokines - physiology Epithelial Cells - physiology Humans Inflammation Mediators - physiology Leukocytes - physiology Medical sciences PGP Pharmacology. Drug treatments Pneumology Pulmonary Disease, Chronic Obstructive - drug therapy Pulmonary Disease, Chronic Obstructive - etiology Pulmonary Disease, Chronic Obstructive - pathology Pulmonary Disease, Chronic Obstructive - physiopathology Toll-like receptor Toll-Like Receptors - drug effects Toll-Like Receptors - physiology β2-adrenoceptor agonist |
title | Cells, mediators and Toll-like receptors in COPD |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T07%3A49%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cells,%20mediators%20and%20Toll-like%20receptors%20in%20COPD&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Sarir,%20Hadi&rft.date=2008-05-13&rft.volume=585&rft.issue=2-3&rft.spage=346&rft.epage=353&rft.pages=346-353&rft.issn=0014-2999&rft.eissn=1879-0712&rft.coden=EJPHAZ&rft_id=info:doi/10.1016/j.ejphar.2008.03.009&rft_dat=%3Cproquest_cross%3E69135958%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69135958&rft_id=info:pmid/18410916&rft_els_id=S0014299908002902&rfr_iscdi=true |